Siglec1-expressing Subcapsular Sinus Macrophages Provide Soil for Melanoma Lymph Node Metastasis
Authors
Affiliations
Lymph nodes (LNs) are a common site of metastasis in solid cancers, and cutaneous melanomas show inherent properties of LN colonization. However, interactions between LN stroma and pioneer metastatic cells during metastatic colonization remain largely uncharacterized. Here we studied mice implanted with GFP-expressing melanoma cells to decipher early LN colonization events. We show that Siglec1-expressing subcapsular sinus (SCS) macrophages provide anchorage to pioneer metastatic cells. We performed in vitro co-culture to demonstrate that interactions between hypersialylated cancer cells and Siglec1 drive the proliferation of cancer cells. When comparing the transcriptome profile of Siglec1-interacting cancer cells against non-Siglec1-interacting cancer cells, we detected enrichment in positive regulators of cell cycle progression. Further, knockout of sialyltransferase compromised the metastatic efficiency of tumor cells by reducing α-2,3-linked sialylation. Thus, the interaction between Siglec1-expressing SCS macrophages and pioneer metastatic cells drives cell cycle progression and enables efficient metastatic colonization.
Ex vivo model of breast cancer cell invasion in live lymph node tissue.
Morgaenko K, Arneja A, Ball A, Putelo A, Munson J, Rutkowski M bioRxiv. 2024; .
PMID: 39091774 PMC: 11291011. DOI: 10.1101/2024.07.18.601753.
Melanoma-derived mediators can foster the premetastatic niche: crossroad to lymphatic metastasis.
Suman S, Markovic S Trends Immunol. 2023; 44(9):724-743.
PMID: 37573226 PMC: 10528107. DOI: 10.1016/j.it.2023.07.002.
Multi-omics analysis of Siglec family genes in cutaneous melanoma.
Li K, Xu N, Guo S Front Immunol. 2023; 14:1036019.
PMID: 37207210 PMC: 10189006. DOI: 10.3389/fimmu.2023.1036019.
Jia Y, Zhang B, Zhang C, Kwong D, Chang Z, Li S Adv Sci (Weinh). 2023; 10(7):e2204565.
PMID: 36709495 PMC: 9982558. DOI: 10.1002/advs.202204565.
Virgilio T, Bordini J, Cascione L, Sartori G, Latino I, Molina Romero D Cancer Immunol Res. 2022; 10(12):1525-1541.
PMID: 36206577 PMC: 9716256. DOI: 10.1158/2326-6066.CIR-22-0225.